

Restarting Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) After Virologic Rebound: A Pooled Analysis of Studies in People With HIV-1

Supplementary Materials

Anton Pozniak,¹ Chloe Orkin,² Franco Maggiolo,³ Yazdan Yazdanpanah,⁴ Axel Baumgarten,⁵ Karam Mounzer,⁶ Michelle L. D'Antoni,⁷ Hailin Huang,⁷ Hui Liu,⁷ Kristen Andreatta,⁷ Laurie VanderVeen,⁷ Christian Callebaut,⁷ Jason T. Hindman,⁷ Hal Martin,⁷ José R. Arribas^{8,9}

¹Chelsea and Westminster Hospital NHS Foundation Trust, London, U.K.; ²Queen Mary University of London, London, U.K.;

³Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; ⁴AP-HP Hôpital Bichat, Paris, France; ⁵Center for Infectious Diseases, Berlin, Germany;

⁶Philadelphia FIGHT, Philadelphia, PA, U.S.A.; ⁷Gilead Sciences, Inc., Foster City, CA, U.S.A.;

⁸Hospital Universitario La Paz, Madrid, Spain; ⁹Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain

Characteristics of Participants With Continued Viremia

Characteristic	Participant						
	1	2	3	4	5	6	7
Overall adherence rate on B/F/TAF, %*	78.0	97.1	98.2	99.6	76.2	99.7	100.0
Duration of continued viremia before discontinuation of B/F/TAF, days	14	87	177	4	30	84	17
Last HIV-1 RNA measurement on B/F/TAF, c/mL	62	14,300	15,900	11,800	1,510	459	248

*Calculated based on pill count.
B/F/TAF, bictegravir/emtricitabine/tenofovir alafenamide; c, copies.